“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Takeda's Partner Merges With Crestovo to Form Finch Therapeutics Group October 22, 2017 Should Biogen Buy Alkermes? February 27, 2018 Japanese Regulators Approve s For Lung Cancer Drug February 2, 2017
